Skip to Content

Innovations in the Management of Neuroendocrine Tumors, An Issue of Endocrinology and Metabolism Clinics of North America, 1st Edition

Author :
Ashley B. Grossman
Date of Publication: 09/2018
This issue of Endocrinology and Metabolism Clinics, edited by Dr. Ashley Grossman, will focus on Innovations in the Management of Neuroendocrine Tumors. Topics include, but are not limited to, Molecular targeted therapy of NETs – State of the art; ...view more
This issue of Endocrinology and Metabolism Clinics, edited by Dr. Ashley Grossman, will focus on Innovations in the Management of Neuroendocrine Tumors. Topics include, but are not limited to, Molecular targeted therapy of NETs – State of the art; Surgical approaches to the management of liver metastases; Liquid biopsies for NETs – circulating tumour cells and DNA; Novel functional imaging of NETs; The problem of appendiceal carcinoids; Peptide radioreceptor therapy comes of age; Current chemotherapy use in NETs; The problem of grade 3 NETs; Molecular genetic studies of pancreatic neuroendocrine tumours reveal new therapeutic approaches; The new WHO classification; Gastrinomas – medical or surgical treatment; When and how to use somatostatin analogues; The NETest as the way forward; Lung and thymic carcinoids; Carcinoid heart disease; Gastric carcinoids; New treatments for the carcinoid syndrome; and The genesis of the NETs concept – From Oberdorfer to 2018.
Add to Cart
This issue of Endocrinology and Metabolism Clinics, edited by Dr. Ashley Grossman, will focus on Innovations in the Management of Neuroendocrine Tumors. Topics include, but are not limited to, Molecular targeted therapy of NETs – State of the art; Surgical approaches to the management of liver metastases; Liquid biopsies for NETs – circulating tumour cells and DNA; Novel functional imaging of NETs; The problem of appendiceal carcinoids; Peptide radioreceptor therapy comes of age; Current chemotherapy use in NETs; The problem of grade 3 NETs; Molecular genetic studies of pancreatic neuroendocrine tumours reveal new therapeutic approaches; The new WHO classification; Gastrinomas – medical or surgical treatment; When and how to use somatostatin analogues; The NETest as the way forward; Lung and thymic carcinoids; Carcinoid heart disease; Gastric carcinoids; New treatments for the carcinoid syndrome; and The genesis of the NETs concept – From Oberdorfer to 2018.

Author Information
By Ashley B. Grossman, BA, BSc, MD, FRCP, FMedSc, Professor of Endocrinology, University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom